Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Regina Fritsche-Danielson
AstraZeneca at ERA 2024: Regina Fritsche-Danielson in an Illuminating Dialogue Exchange with PharmaShots
Shots:  Associated with early onset and rapid progression of chronic kidney disease (CKD), APOL1 Mediated Kidney Disease dramatically affects people of African descent  AstraZeneca is developing AZD2373, the first potential precision treatment option for the treatment of AMKD with Ionis Pharmaceuticals. Recently, AZ shared promising data from the early P-I data from the MAD study …
August 26, 2024
Viewpoints_Manojkumar Bupathy
Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots
Shots:  Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers  Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma   The study reveals that four out of the ten patients received only…
August 20, 2024
Viewpoints_Jennifer Fernandez
TCOC Management in Oncology: Jennifer Fernandez from The Oncology Network in a Dialogue Exchange with PharmaShots
Shots:  Prominent oncology drugs like pembrolizumab and nivolumab were initially approved with weight-based dosing and gradually transitioned to fixed dozing. With the transformation in the dosing model, the average dose amount administered to patients increased dramatically in the Oncology Care Model  Today, at PharmaShots, we have Jennifer Fernandez from The Oncology Network, shedding light on…
August 7, 2024
Viewpoints_Jane Chung
Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots
Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…
July 24, 2024
Viewpoints_Mina Makar
Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots
Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024
Load more